BEPOTASTINE BESILATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BEPOTASTINE BESILATE (BEPOTASTINE BESILATE).
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
| Metabolism | Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and oxidation (CYP3A4 minor pathway). |
| Excretion | Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%). |
| Half-life | Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis. |
| Protein binding | Approximately 55-60% bound to human plasma proteins, primarily albumin. |
| Volume of Distribution | Following oral administration, Vd is 1.4-1.8 L/kg, indicating extensive tissue distribution. Not applicable for ophthalmic use. |
| Bioavailability | Oral bioavailability is <1% due to extensive first-pass metabolism. Ophthalmic: Systemic absorption negligible (<0.5%). |
| Onset of Action | Ophthalmic: Within 3 minutes after topical administration; reaches maximum effect by 15 minutes. |
| Duration of Action | Duration of therapeutic effect is 8-12 hours following ophthalmic administration, supporting twice-daily dosing. |
| Molecular Weight | 388.4 |
2 mg/mL ophthalmic solution: 1 drop in each affected eye twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | ≥2 years: same as adult dose (1 drop in each affected eye twice daily). |
| Geriatric use | No dose adjustment required; same as adult dosing. |
| 1st trimester | Insufficient data in humans; animal studies show no teratogenicity at high doses. Use only if clearly needed. |
| 2nd trimester | Insufficient data; may be used with caution if benefit outweighs risk. |
| 3rd trimester | Insufficient data; avoid near term due to potential anticholinergic effects. |
Clinical note
Comprehensive clinical and safety monograph for BEPOTASTINE BESILATE (BEPOTASTINE BESILATE).
| Placental transfer | Likely crosses placenta due to low molecular weight (mupirocin reference: 388.4 Da), but specific data lacking. |
| Breastfeeding | Not recommended; may be excreted in milk; potential for anticholinergic effects in infant. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to bepotastine or any component
| Precautions | May cause severe hypersensitivity reactions (angioedema, bronchospasm)., Avoid use in patients with known hypersensitivity to bepotastine., Ophthalmic use: do not wear contact lenses during treatment; may cause transient burning/stinging., Systemic use: caution in patients with renal impairment (dose adjustment required)., Avoid concurrent use with CNS depressants due to additive sedative effects. |
| Food/Dietary | No clinically significant food interactions reported with ophthalmic use. |
| Clinical Pearls |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose) and 100 mg/kg/day in rabbits (approximately 200 times the human clinical dose), but there are no adequate and well-controlled studies in pregnant women. During the first trimester, the risk is unknown; during the second and third trimesters, potential risks to the fetus cannot be excluded. |
| Fetal Monitoring | No specific maternal or fetal monitoring is routinely required for topical ophthalmic use due to minimal systemic absorption. However, for systemic administration, monitor for CNS effects (sedation, dizziness) and anticholinergic effects. In pregnant patients, consider fetal monitoring per standard obstetric care if systemic exposure is significant. |
| Fertility Effects | No studies on human fertility have been conducted. In animal studies, bepotastine besilate had no effects on male or female fertility at oral doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose). The clinical relevance of this finding is unknown. |
| Bepotastine besilate is a selective histamine H1 receptor antagonist used topically for allergic conjunctivitis. Avoid use with contact lenses; remove before instillation and wait at least 10 minutes before reinserting. Systemic absorption is minimal, but caution in patients with severe hepatic impairment. Onset of action is within 15 minutes, duration 8 hours. Do not touch dropper tip to eye or surrounding surfaces. |
| Patient Advice | Wash hands before use. · Tilt head back, pull lower eyelid down, and instill one drop in the affected eye(s) twice daily. · Do not touch the dropper tip to your eye or any surface. · Remove contact lenses before use and wait at least 10 minutes before reinserting. · Do not use if solution changes color or becomes cloudy. · Common side effects include mild eye irritation, bitter taste, or headache. · If you experience eye pain, vision changes, or redness, contact your doctor. |